Skip to content

Solution

NeoZenome employs the following two dimensional approach in terms of solutions offered to the respective market segments: 

  1. Providing Clinical Decision Support Services to Hospitals / Physicians
  2. Providing Drug Research Support Services to drug manufacturing companies.

For Physicians

Following are the basket of services offered to hospitals / physicians.

  1. Baseline Remission
  2. Follow Up Care
  3. Biomarker Identification
  4. Stratification Platform

1 – BASELINE REMISSION

Starting Materials

  • 1 FFPE block and/or 2×10 ml of patient blood

Integrative Molecular Profiling

  • Unbiased Whole Exome Sequencing (WES)
  • Unbiased RNA sequencing (RNA seq.)
  • Unbiased proteomic profiling
  • Tumor Mutation Burden (TMB)
  • Microsatellite Instability (MSI)

Phenotypic Characterization

  • Test the effect of Variant of unknown clinical significance (VUS)
  • Test the effect of drug or drug combination of VUS on 2D, 3D Growth, Migration using In Vitro and In vivo models.
  • Generation of individual patient derived xenografts (PDXs) and test the predicted combination on tumor growth.

Pathology Services

  • IHC for targeted therapies
  • FISH, In situ hybridization to validate gene fusions
  • IHC and FACS analysis for immune therapy

Comprehensive Clinical Actionable Patient Reports

  • Treatment options for targeted therapy, immunotherapy
  • Clinical trials accessibility

2 – FOLLOW UP CARE

NeoZenome follows patient therapeutic response by re-sequencing from patient blood sample using WES, RNA seq. and tailored targeted and/or immune therapeutic options.

Starting Materials

  • 2×10 ml of patient blood

Integrative Molecular Profiling

  • Unbiased Whole Exome Sequencing (WES)
  • Unbiased RNA sequencing (RNA seq.)
  • Unbiased proteomic profiling
  • Tumor Mutation Burden (TMB)
  • Microsatellite Instability (MSI)

Phenotypic Characterization

  • Test the effect of Variant of unknown clinical significance (VUS)
  • Test the effect of drug or drug combination of VUS on 2D, 3D Growth, Migration using In Vitro and In vivo models.
  • Generation of individual patient derived xenografts (PDXs) and test the predicted drug combination on tumor growth.

Pathology Services

  • IHC
  • Histology based mass spectrometry profiling
  • FISH, In situ hybridization to validate gene fusions
  • IHC and FACS analysis for immune therapy

Comprehensive Clinical Actionable Patient Reports

  • Treatment options for targeted therapy, immunotherapy
  • Dynamic evolution of secondary driver variants report
  • Clinical trials accessibility

3 – BIOMARKER IDENTIFICATION

NeoZenome focuses on WES, RNA seq, proteomics, and metabolomics analysis and generates actionable biomarkers discovery for tailored targeted and/or immune therapeutic options. Biomarker identification supports both baseline remission and follow-up care.

Starting Materials

  • 1 FFPE block and/or 2×10 ml of patient blood

Integrative Molecular Profiling

  • Unbiased Whole Exome Sequencing (WES)
  • Unbiased RNA sequencing (RNA seq.)
  • Unbiased proteomic profiling
  • Unbiased Metabolome profiling
  • Tumor Mutation Burden (TMB)
  • Microsatellite Instability (MSI)

Phenotypic Characterization

  • Test the effect of Variant of unknown clinical significance (VUS)
  • Test the effect of drug or drug combination of VUS on 2D, 3D Growth, Migration using In Vitro and In vivo models.
  • Generation of individual patient derived xenografts (PDXs) and test the predicted combination on tumor growth.

Pathology Services

  • IHC for targeted therapies
  • FISH, In situ hybridization to validate gene fusions
  • IHC and FACS analysis for immune therapy

Comprehensive Clinical Actionable Patient Reports

  • Integrated biomarker profiling associated with sensitive or resistance to therapy
  • Treatment options for targeted therapy, immunotherapy
  • Clinical trials accessibility

4 – STRATIFICATION PLATFORM

NeoZenome focuses on WES, RNA seq, and proteomics analysis and stratifies patients based on the predictive (sensitive or resistance) biomarkers using our proprietary AI coupled with knowledge of database. Stratification platform helps in both baseline remission and follow-up care.

Starting Materials

  • 1 FFPE block and/or 2×10 ml of patient blood

Integrative Molecular Profiling

  • Unbiased Whole Exome Sequencing (WES)
  • Unbiased RNA sequencing (RNA seq.)
  • Unbiased proteomic profiling
  • Tumor Mutation Burden (TMB)
  • Microsatellite Instability (MSI)

Phenotypic Characterization

  • CRISPR screens, proteomic screens in response to resistance and/or sensitive driver mutations, copy number gain/loss, and gene fusions for druggable candidate discovery
  • Test the effect drugs targeting top 2 candidates identified from the CRISPR and proteomic screens.

Comprehensive Clinical Actionable Patient Reports

  • Treatment options using preclinical tested combinatorial-targeted therapy, immunotherapy.
  • Clinical trials accessibility.

For Pharma

Following are the basket of services offered to pharma companies.

  • Drug Repurposing
  • Drug Discovery Platform
  • Biomarker Identification
  • Stratification Platform

Drug Repurposing

NeoZenome undertakes Drug Repurposing assignments for Pharmaceutical/Drug development companies on Contract Research basis. Our State-of-the-Art AI platform coupled with phenotypic/biological platform supports this activity. It predicts appropriate and validate drugs to tailored cohorts.

Drug Discovery Platform

NeoZenome has been testing, preclinically, novel immune checkpoint compounds using in vivo models. Successful completion of preclinical testing helps assessing the clinical efficacy of these novel compounds in Phase II clinical trials across all cancer types in a basket trial setting.

Biomarker Identification

NeoZenome focuses on WES, RNA seq, proteomics, and metabolomics analysis and generate actionable biomarkers discovery for tailored targeted and/or immune therapeutic options.

Stratification Platform

NeoZenome focuses on WES, RNA seq, and proteomics analysis and stratifies patients based on the predictive (sensitive or resistance) biomarkers using our proprietary AI coupled with knowledge of database.